"The new guidelines risk returning us to the bad old days when NIH inventions gathered dust on the shelf. The administration has claimed this is being done 'to expand patient access to products that emerge from NIH-owned inventions.'"
"While the Bayh-Dole Act requires potential licensees to submit 'a plan for development and/or marketing of the invention', the new guidelines require applicants to address additional topics demonstrating how resulting products will be available, affordable, acceptable and sustainable."
Collection
[
|
...
]